Delta4 uses AI platform and computational biology to identify potential of clopidogrel for FSGS

June 20, 2023

Delta4 GmbH has announced the identification of a potential new therapeutic option for the treatment of focal segmental glomerulosclerosis (FSGS).

BioWorld Science Artificial intelligence Nephrology

Today's news in brief

BioWorld

BioWorld briefs for April 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 21, 2025.

Makary’s vision for slimmed-down US FDA somewhat reassuring

BioWorld

Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...

Ouch! Tariffs hit med tech harder than expected

BioWorld MedTech

First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...